At a meeting held on Friday 27 May 2022, the National Advisory Committee on Vaccination of the Ministry of Health, recommended that the vaccinia Ankara (MVA-BN) (Imvanex) vaccine,[/B] which has been licensed by the European Medicines Agency (EMA) in 2013, for the prevention of smallpox and which is recommended in a two-dose regimen, may be used for the prevention of monkeypox.
This vaccine is recommended internationally for the prevention and treatment of monkeypox (reported efficacy 85%).
It is recommended that this vaccine is available for targeted administration to specific high-risk groups, such as:
- healthcare professionals who will be called upon to manage possible suspected or confirmed cases, before or after exposure,
- individuals,close contacts of a confirmed case, after exposure.
It is recommended that it be administered within 4 days of the date of exposure, to prevent the occurrence of disease.
The National Advisory Committee on Vaccination, in collaboration with the Infectious Disease Surveillance and Control Unit of the Medical and Public Health Services of the Ministry of Health, is monitoring the epidemiological data and reserves the right to vary the plan according to developments.
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source
